Use of riluzole prodrugs to treat Alzheimer's disease

Patent metadata

Field	Value
Publication number	US-12201618-B2
Application number	US-202117151577-A
Country	US
Kind code	B2
Filing date	Jan 18, 2021
Priority date	Jan 18, 2017
Publication date	Jan 21, 2025
Grant date	Jan 21, 2025

Abstract

Disclosed are methods of treating Alzheimer's Disease by administering to a patient in need thereof a riluzole prodrug such as troriluzole. Pharmaceutical compositions and kits including the riluzole prodrugs are also disclosed.

First claim

What is claimed is:

1. A method of treating Alzheimer's Disease of mild to moderate severity in a patient in need thereof, the method comprising administering to the patient a riluzole prodrug having the following formula:

wherein the riluzole prodrug is administered to the patient at a dosage of 280 mg once per day or a dosage of 140 mg twice per day.

2. The method of claim 1 , wherein the riluzole prodrug is administered to the patient in the form of a capsule.

3. The method of claim 1 , wherein the riluzole prodrug is administered to the patient for a duration of from the onset of treatment to the end of the patient's life.

4. A method for improving a response in a patient afflicted with Alzheimer's disease of mild to moderate severity, the method comprising administering to the patient in need thereof, an effective amount of a riluzole prodrug having the following formula:

wherein the riluzole prodrug is administered to the patient at a dosage of 280 mg once per day or at a dosage of 140 mg twice per day.

5. The method of claim 4 , wherein the improved response is one or more of overall survival, quality of life, overall response rate, duration of response, delay of onset, or patient reported outcome.

6. A kit for treating a patient afflicted with Alzheimer's Disease of mild to moderate severity, the kit comprising:
(a) a riluzole prodrug; and
(b) instructions for administering the riluzole prodrug in the method of claim 1 ,
wherein the riluzole prodrug has the following formula:

wherein a daily dosage of the riluzole prodrug in the kits is 280 mg.

7. A kit for improving a response in a patient afflicted with Alzheimer's Disease of mild to moderate severity, the kit comprising:
(a) a riluzole prodrug; and
(b) instructions for administering the riluzole prodrug in the method of claim 4 ,
wherein the riluzole prodrug has the following formula:

wherein a daily dosage of the riluzole prodrug in the kit is 280 mg.

Assignees

• Biohaven Therapeutics Ltd

Inventors

• Coric Vladimir
• Berman Robert
• Qureshi Irfan

Classifications

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• A61K9/48

  Preparations in capsules, e.g. of gelatin, of chocolate {(A61K9/0004 takes precedence; bite capsules A61K9/0056)} · CPC title

• A61K9/4866

  Organic macromolecular compounds · CPC title

• A61K9/4858

  Organic compounds · CPC title

• A61K9/2054

  Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose · CPC title